NHS losing millions in pharma cost-sharing schemes

Sharing the cost of expensive new cancer medicine with drugs companies is becoming increasingly common.

Bureaucracy may be blocking millions of pounds for which the NHS can be reimbursed, according to a survey of 31 health trusts in England.

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • 10 expert briefings every fortnight (Premium only)
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)

Already a subscriber? Sign into your account here